Perform efficacy evaluations of candidate therapeutic agents against CRYPTOCOCCUS NEOFORMANS in a standardized, validated mouse model of acute cryptococcal infection of the central nervous systemEvaluate therapeutic agents for efficacy against CRYPTOCOCCUS NEOFORMANS in standardized, reproducible, and validated IN VITRO culture test system which employs intact organism for determination of minimal inhibitory concentration (MIC) and minimal lethal concentration (MLC); and provide a quantitative assessment of cytotoxicity of the test therapies.
